We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TriLink BioTechnologies Announces Supply Agreement with Osmetech Molecular Diagnostics
News

TriLink BioTechnologies Announces Supply Agreement with Osmetech Molecular Diagnostics

TriLink BioTechnologies Announces Supply Agreement with Osmetech Molecular Diagnostics
News

TriLink BioTechnologies Announces Supply Agreement with Osmetech Molecular Diagnostics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TriLink BioTechnologies Announces Supply Agreement with Osmetech Molecular Diagnostics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TriLink BioTechnologies, Inc. has announced that it has signed a service agreement with Osmetech Molecular Diagnostics to supply reagents for Osmetech's recently launched eSensor® Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor® XT-8 System for Warfarin sensitivity.

As part of the agreement, TriLink is providing Osmetech with custom oligonucleotides, which are required reagents for the eSensor® detection systems.

"TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor® products in the marketplace to date," said Osmetech Molecular Diagnostics COO, Pankaj Singhal.

"TriLink is proud to work with Osmetech in the advancement of this important science and rapidly developing commercial opportunity," said TriLink CEO, Dr. Richard Hogrefe.
Advertisement